Omeros drug fails a PhI­II kid­ney tri­al, stock near­ly halved

Omeros said Mon­day that its treat­ment can­di­date for a cer­tain kid­ney dis­ease failed a Phase III study, and in­vestors shaved near­ly half the share price $OMER in re­ac­tion to the news.

The late-stage flop in im­munoglob­u­lin A nephropa­thy, or IgAN, is a blow to Omeros’ pipeline-in-a-prod­uct plans for nar­so­plimab.

Omeros will end the ARTEMIS-IGAN study, giv­en it missed the mark in the IgA nephropa­thy tri­al, which failed to reach sta­tis­ti­cal sig­nif­i­cance on re­duc­ing more el­e­vat­ed pro­tein in urine than place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER